Huntington’s Disease – Landscape & Forecast – Disease Landscape & Forecast
Huntington’s disease (HD) is a rare progressive neurological disorder characterized by movement disorders, cognitive decline, behavioral changes, and psychiatric disturbances. Current treatment is entirely dependent on symptomatic therapies and includes a cocktail of antidepressants, antipsychotics, and antiepileptics to control patients’ cognitive, behavioral, and neurological symptoms. Treatment for chorea is limited to tetrabenazine and Teva’s Austedo (deutetrabenazine), which launched in 2017 in the United States. HD is a debilitating condition, and available treatments are only marginally effective, leaving tremendous need for effective disease-modifying therapies (DMTs). Ionis/Roche’s HTTRx/RG6042 is an antisense oligonucleotide being evaluated in Phase III trials for HD. The therapy has the potential to modify disease course and, accordingly, has garnered interest among treating physicians. Furthermore, the Phase II HD pipeline also includes a variety of additional symptom-targeting and potential disease-modifying therapies, any of which stands to capitalize on the significant commercial opportunity in HD if its efficacy is demonstrated.
Questions Answered
- How large is the diagnosed Huntington’s population in the United States and EU5? How will the population change by 2029?
- What is the current treatment landscape in Huntington’s disease, and how will it change in the next ten years?
- What do key opinion leaders view as the greatest unmet medical needs in the management of Huntington’s disease?
- What do neurologists consider the most promising emerging therapies for HD to be, and which are likely to launch by 2029?
Product Description
Niche & Rare Disease Landscape & Forecast: comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Table of contents
- Huntington's Disease - Landscape & Forecast - Disease Landscape & Forecast
- COVID-19
- Key Findings
- Huntington's Disease - Key Findings 2020
- Commercial Outlook
- Key Findings
- Regional Sales of Key Therapies to Treat Huntington's Disease: 2019 and 2029
- Huntington's Disease SWOT Analysis
- Drivers and Constraints
- What Factors Are Driving Sales in Huntington's Disease?
- What Factors Are Constraining Sales in Huntington's Disease?
- Dopamine-Depleting Agent-Specific Trends
- Antisense oligonucleotides
- Alternative Market Scenarios
- Alternative Scenarios for the Huntington's Disease Market Through 2029
- Key Findings
- Forecast
- Sales of Key Therapies in Huntington's Disease
- Etiology and Pathophysiology
- Disease Overview
- Etiology
- Relationship between CAG Repeats and Huntingtonu2019s Disease
- Inheritance Patterns in Huntingtonu2019s Disease
- Pathophysiology
- Select Brain Areas Affected by Neuronal Loss During Huntington's Disease Progression
- Clinical Presentation and Symptomology in Adult-Onset Huntington's Disease
- Symptom Progression in Adult-Onset Huntington's Disease
- Juvenile Huntingtonu2019s Disease
- Key Pathways and Drug Targets
- Disease Overview
- Epidemiology
- Introduction
- Key Findings
- Diagnosed Manifest Prevalent Cases of Huntington's Disease per 100,000 Among People of All Ages in 2019 and 2029
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Manifest Prevalent Cases of Huntington's Disease over the Next 10 Years
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Diagnosed Manifest Prevalence of Huntington's Disease
- Diagnosed Manifest Prevalent Cases of Huntington's Disease
- Sources Used for Drug-Treated Cases of Huntington's Disease
- Drug-Treated Cases of Huntington's Disease
- Introduction
- Current Treatment
- Key Findings
- Diagnosis
- Diagnostic Tests and Staging
- Progression of Manifest Huntington's Disease
- Treatment Providers and Referral Patterns
- Expert Insight: Diagnosis of Huntington's Disease
- Treatment Goals
- Key Endpoints Used in Clinical Trials for Huntington's Disease
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Huntington's Disease
- Current Treatments Used for Huntington's Disease
- Clinical Trial Outcomes for Tetrabenazine
- Advantages and Disadvantages of Tetrabenazine
- Expert Insight: Tetrabenazine
- Clinical Trial Outcomes for Deutetrabenazine
- Advantages and Disadvantages of Deutetrabenazine
- Key Results from Select Clinical Trials Investigating Deutetrabenazine for the Treatment of Huntington's Disease
- Ongoing Clinical Development of Deutetrabenazine
- Key Ongoing Clinical Trials of Deutetrabenazine
- Expert Insight: Deutetrabenazine
- Clinical Trial Outcomes for Antidepressants
- Advantages and Disadvantages of Antidepressants
- Key Results from Select Clinical Trials Investigating Antidepressants for the Treatment of Huntington's Disease
- Expert Insight: Antidepressants
- Clinical Trial Outcomes for Antipsychotics
- Advantages and Disadvantages of Antipsychotics
- Key Results from Select Clinical Trials Investigating Antipsychotics for the Treatment of Huntington's Disease
- Ongoing Clinical Development of Antipsychotics
- Expert Insight: Antipsychotics
- Clinical Trial Outcomes for Antiepileptic Mood Stabilizers
- Advantages and Disadvantages of Antiepileptic Mood Stabilizers
- Key Results from Select Clinical Trials Investigating Antiepileptic Mood Stabilizers for the Treatment of Huntington's Disease
- Medical Practice
- Overview
- Generalized Treatment Decision Tree for Chorea in Huntington's Disease
- Generalized Treatment Decision Tree for Psychiatric Disturbances in Huntington's Disease
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in Huntington's Disease
- Top Unmet Needs in Huntington's Disease: Current and Future Attainment
- Expert Insight: Unmet Need in Huntington's Disease
- Emerging Therapies
- Key Findings
- Pipeline Trends for Huntington's Disease
- Key Emerging Therapies
- Notable Developments Among Key Emerging Therapies for Huntington's Disease
- Key Therapies in Development for Huntington's Disease
- Valbenazine Profile
- Key Ongoing Clinical Trials of Valbenazine in the Treatment of Huntington's Disease
- Analysis of the Clinical Development Program for Valbenazine
- Expert Insight: Valbenazine
- Expectations for Launch and Sales Opportunity of Valbenazine in Huntington's Disease
- Laquinimod Profile
- Analysis of the Clinical Development Program for Laquinimod
- Expert Insight: Laquinimod
- Expectations for Launch and Sales Opportunity of Laquinimod in Huntington's Disease
- RG6042 Profile
- Key Ongoing Clinical Trials of RG6042 in the Treatment of Huntington's Disease
- Analysis of the Clinical Development Program for RG6042
- Expert Insight: RG6042
- Expectations for Launch and Sales Opportunity of RG6042 in Huntington's Disease
- Early-Phase Pipeline Analysis
- Notable Developments in the Early-Phase Pipeline for Huntington's Disease
- Select Phase II Compounds in Development for Huntington's Disease
- Select Compounds in Early-Phase Development for Huntington's Disease
- Patient Registries
- Patient Registries for Huntington's Disease
- Prominent Huntington's Disease Patient Organizations
- Orphan-Drug Designation
- Key Findings
- Access & Reimbursement Overview
- Region-Specific Reimbursement Practices
- General Reimbursement Environment: United States
- General Reimbursement Environment: EU5
- Looking for More?
- Region-Specific Reimbursement Practices
- Appendix
- Key Abbreviations Related to Huntington's Disease
- Brands, Marketers, and Generic Availability of Key Therapies for Huntington's Disease by Market
- Huntington's Disease Bibliography
- COVID-19
Raina Priyadarshini, Ph.D., is a senior analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. Previously, she was an analyst in the biopharmaceutical industry, where she developed novel disease target-drug combinations for rare CNS and hematological disorders. Dr. Priyadarshini trained as a molecular biologist; her research focused on the interplay between tumor suppressor proteins and oncoproteins. She received her doctorate from the National Institute of Immunology.